405 related articles for article (PubMed ID: 36630066)
1. Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin.
Ly S; Nedosekin D; Wong HK
Am J Clin Dermatol; 2023 Mar; 24(2):247-273. PubMed ID: 36630066
[TBL] [Abstract][Full Text] [Related]
2. Rituximab biosimilars.
Vital EM; Kay J; Emery P
Expert Opin Biol Ther; 2013 Jul; 13(7):1049-62. PubMed ID: 23600760
[TBL] [Abstract][Full Text] [Related]
3. The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.
Brown JR; Cymbalista F; Sharman J; Jacobs I; Nava-Parada P; Mato A
Oncologist; 2018 Mar; 23(3):288-296. PubMed ID: 29212732
[TBL] [Abstract][Full Text] [Related]
4. Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.
Levesque MC
Clin Exp Immunol; 2009 Aug; 157(2):198-208. PubMed ID: 19604259
[TBL] [Abstract][Full Text] [Related]
5. Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases.
Mostkowska A; Rousseau G; Raynal NJ
FASEB J; 2024 Mar; 38(5):e23536. PubMed ID: 38470360
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in treatment-resistant autoimmune blistering skin disorders.
Schmidt E; Bröcker EB; Goebeler M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):56-64. PubMed ID: 18270859
[TBL] [Abstract][Full Text] [Related]
7. B cells as therapeutic targets for rheumatic diseases.
Looney RJ; Anolik J; Sanz I
Curr Opin Rheumatol; 2004 May; 16(3):180-5. PubMed ID: 15103242
[TBL] [Abstract][Full Text] [Related]
8. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).
Arzoo K; Sadeghi S; Liebman HA
Ann Rheum Dis; 2002 Oct; 61(10):922-4. PubMed ID: 12228164
[TBL] [Abstract][Full Text] [Related]
9. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
Tanaka Y
Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
[TBL] [Abstract][Full Text] [Related]
10. [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases].
Kasperkiewicz M; Zillikens D
Hautarzt; 2007 Feb; 58(2):115-6, 118-21. PubMed ID: 17237928
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder.
Salopek TG; Logsetty S; Tredget EE
J Am Acad Dermatol; 2002 Nov; 47(5):785-8. PubMed ID: 12399777
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.
Dierickx D; Delannoy A; Saja K; Verhoef G; Provan D
Am J Hematol; 2011 Mar; 86(3):278-91. PubMed ID: 21328427
[TBL] [Abstract][Full Text] [Related]
13. [Rituximab and autoimmune disorders therapy].
Quint L
Rev Med Interne; 2004 Oct; 25(10):752-4. PubMed ID: 15471601
[TBL] [Abstract][Full Text] [Related]
14. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
15. Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease.
Li Y; Foshee JB; Sontheimer RD
J Am Acad Dermatol; 2011 Apr; 64(4):773-8. PubMed ID: 20494477
[TBL] [Abstract][Full Text] [Related]
16. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.
Vital EM; Wittmann M; Edward S; Md Yusof MY; MacIver H; Pease CT; Goodfield M; Emery P
Arthritis Rheumatol; 2015 Jun; 67(6):1586-91. PubMed ID: 25707733
[TBL] [Abstract][Full Text] [Related]
17. The potential utility of B cell-directed biologic therapy in autoimmune diseases.
Arkfeld DG
Rheumatol Int; 2008 Jan; 28(3):205-15. PubMed ID: 17957371
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for autoimmune blistering diseases: recent studies, new insights.
Lunardon L; Payne AS
G Ital Dermatol Venereol; 2012 Jun; 147(3):269-76. PubMed ID: 22648328
[TBL] [Abstract][Full Text] [Related]
19. Biologics in autoimmune bullous diseases: Current scenario.
Bishnoi A; De D; Handa S; Mahajan R
Indian J Dermatol Venereol Leprol; 2021; 87(5):611-620. PubMed ID: 34245525
[TBL] [Abstract][Full Text] [Related]
20. The need for markers and predictors of Rituximab treatment resistance.
Sitaru C; Thiel J
Exp Dermatol; 2014 Apr; 23(4):236-7. PubMed ID: 24450995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
